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Biophysics 
 
 
 
The purpose of this study was to identify the effects of a hemoglobin-based 
oxygen carrier, HBOC-201, on the cardiovascular system. Systemic 
cardiovascular parameters of mean arterial pressure (MAP), pulse pressure, 
heart rate, and oxygen saturation, as well as vascular resistance, were 
examined. A murine model of the cardiovascular system and microvasculature 
was employed. Sprague-Dawley rats (male; 230-530g; N = 13) were 
anaesthetised and surgically prepared for intravital microscopy of the 
spinotrapezius muscle. Increasing doses of HBOC-201 (2 mg/kg, 22 mg/kg, 230 
mg/kg, and 780 mg/kg) and an iso-oncotic volume control were administered to 
assess for a dose-response relationship. MAP displayed a significant increase 
from baseline for both treatment groups, with no significant difference between 
the two. Arteriolar diameter displayed no changes from baseline, or between 
treatment groups or across doses. Based on these results, the noted changes in 
MAP were due to hypervolemia, and not a property of HBOC-201, itself. 
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Introduction 
Trauma and associated hemorrhage often result in the development of 
hypovolemic shock and subsequent tissue and cell death due to ischemia. Many 
patients suffering from traumatic injury often require massive blood product 
transfusion in order to maintain blood pressure, tissue oxygenation, and normal 
coagulation status(Hess, Holcomb, & Hoyt, 2006). This massive transfusion is 
often defined as 10 or more units of packed red blood cells (PRBCs) in a 24-hour 
period, worsening the prognosis for these patients and increasing mortality. 
Currently, blood product transfusion is the standard of care for hemorrhaging 
trauma patients, along with crystalloid fluid administration to restore volume 
quickly(Como, Dutton, Scalea, Edelman, & Hess, 2004; Davis, Johannigman, & 
Pritts, 2012; Geeraedts, Kaasjager, van Vugt, & Frolke, 2009; Harris, Thomas, & 
Brohi, 2012; Holcomb et al., 2008). Unfortunately, many areas of the world do not 
have ready access to blood products, and those that do face the challenge of 
finding enough donors to meet the demand. Without an adequate and consistent 
source of human blood products, the goal of maintaining tissue perfusion may 
often be unobtainable. 
Efficient transport of respiratory gases is imperative for the maintenance of 
tissue perfusion. As stated earlier, large-volume crystalloid fluid administration is 
used to restore volume quickly. However, it comes at a price. Without 
administration of additional oxygen-carrying red blood cells (RBCs), the patient 
will develop a condition termed isovolemic anemia. This occurs in the presence 
of adequate blood volume, but low or inadequate hemoglobin 
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concentration(Gutierrez, Reines, & Wulf-Gutierrez, 2004). This condition has 
been documented as normal for certain patient populations (e.g.: renal failure), 
and benign in healthy volunteers, but does come with certain physiological 
characteristics. In a study of healthy volunteers subjected to acute isovolemic 
hemodilution to a hemoglobin level of 5 g/dL (normal range = 12-17 g/dL), 
subjects demonstrated significant increases in heart rate, stroke volume, and 
cardiac index (!" = !"!"# = !"∗!"!"# ), though hypoxia was absent(Weiskopf et al., 
1998). While not detrimental to healthy individuals, these physiological changes 
almost certainly impact the outcome of a patient experiencing hemorrhagic 
shock. 
 The problem of supply versus demand has plagued blood product therapy 
since its beginning, and with growing populations, has only gotten worse. Many 
research groups have attempted to solve this issue by developing blood product 
replacements such as artificial oxygen carriers, plasma and platelets. Many of 
these products have extended shelf lives, wide environmental ranges, and can 
be mass-produced(Greenburg & Kim, 2004). These attributes make blood 
product replacements a desirable area of focus, though many issues have been 
found with those currently in development. These side effects, some of which will 
be discussed in detail later, serve as a roadblock for the industry, preventing 
many products from ever reaching the market. It is only through understanding 
the mechanisms behind such effects that safe and reliable replacements can be 
created. The main area of interest for this project involves artificial red blood cell 
replacements, otherwise known as hemoglobin-based oxygen carriers (HBOCs). 
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Hemoglobin-based oxygen carriers are natural or synthetic red blood cell 
substitutes that were originally designed to enhance the transport of respiratory 
gases in patients suffering from hemorrhagic shock or general hypovolemia. 
Ideally, these solutions are shelf-stable and readily exchange oxygen with the 
surrounding tissue, acting as a suitable transfusion in lieu of whole blood or 
packed red blood cells(Hughes et al., 1996). Their designs are generally 
proprietary, but often include some form of crosslinking or polymerization that 
results in differing sizes of “particles” depending on the manufacturer (Greenburg 
& Kim, 2004; Sakai et al., 2000; Silverman, Weiskopf, & Planning Committee and 
the Speakers, 2009; Tsai et al., 2006). 
In order to understand how HBOCs affect blood pressure, it is important to 
understand the mechanisms by which blood pressure is normally regulated. 
There are many systems and pathways that interact with each other and keep 
each other in check to achieve homeostasis. Of particular interest in this 
investigation, nitric oxide (NO) is a prime example of a regulatory molecule that 
produces vasodilation. Likewise, endogenous catecholamines produce 
vasoconstriction, which leads to an increase in blood pressure. It is this constant 
balancing act between hypotensive and hypertensive mechanisms that goes 
awry in the presence of an outside force, such as disease, trauma, or 
pharmacotherapeutics. 
Nitric oxide (NO) is an important gaseous, free radical molecule that is 
involved in many processes as a messenger(Lowenstein, Dinerman, & Snyder, 
1994). NO is synthesised endogenously by nitric oxide synthase (NOS), which is 
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found in the endothelium (eNOS), neuronal system (nNOS), and as an immune 
system inducible isoform (iNOS). Each of these is a known constituent of their 
respective tissues, and has the ability to catalyze a number of reactions that 
generate NO from its precursor, L-arginine(Knowles & Moncada, 1994). Of 
particular importance to the topic at hand is eNOS, which as stated before, is 
found in vascular endothelial cells. 
The synthesis of NO in the vascular system helps to regulate blood 
pressure by direct stimulation of vascular smooth muscle adjacent to the 
endothelium(Rees, Palmer, & Moncada, 1989; Umans & Levi, 1995). NO has an 
affinity for the iron molecules of endogenous heme groups that is much higher 
than that of oxygen and respiratory gases. This affinity leads to NO binding of 
heme on guanylate cyclase, activating the enzyme that leads to production of 
cyclic guanosine monophosphate (cGMP) and subsequent muscle 
relaxation(Ignarro, 1991; Lowenstein et al., 1994). Though direct muscle 
relaxation is a significant mechanism in the role of NO in vascular tone, it is not 
the only one. 
Nitric oxide acts centrally on the sympathetic nervous system, as well as 
peripherally by upregulation of endothelin (ET) receptors. Direct injection of NO 
into the central nervous system has demonstrated a small, but significant 
vasoconstriction response that can be terminated by transection of the spinal 
cord (Togashi et al., 1992). Similarly, NO is thought to play a role in regulation of 
the potent vasoactive peptide, ET. This 21-amino acid polypeptide binds to 
several receptors, and derives its vasoconstrictor actions from the ET-A receptor 
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subtype. Binding of endothelin to ET-A directly stimulates smooth muscle 
contraction, resulting in an increase in blood pressure (Redmond, Cahill, Hodges, 
Zhang, & Sitzmann, 1996; Rubanyi & Polokoff, 1994). 
Cell free hemoglobin has the ability to scavenge nitric oxide from the blood 
and chemically alter their forms (methemoglobin and nitrate [NO3-], respectively) 
(Doherty et al., 1998; Huang et al., 2005; Olson et al., 2004; Smani, Fifre, 
Labrude, Vigneron, & Faivre, 2007; Tsai et al., 2006; Yu et al., 2010). This 
scavenging and subsequent loss of the vasoregulatory agent, NO, leads to 
marked increases in blood pressure, one of the side effects that has kept HBOCs 
from being introduced to the market(Alayash, 1999; Angele, Schneider, & 
Chaudry, 2008; Fitzpatrick, Savage, Kerby, Clouse, & Kashyap, 2004; Olson et 
al., 2004; Tsai et al., 2006; Yu et al., 2010). In the case of major traumatic 
hemorrhage, it has been found prudent to titrate volume replacements to a 
systolic blood pressure of 90-100 mmHg in order to decrease instances of 
bleeding while maintaining perfusion. Systolic blood pressures of greater than 
100 mmHg are detrimental to hemostasis, and do not enhance vital perfusion 
already taking place. Hence, HBOC-induced blood pressure changes currently 
make this an unsuitable treatment for this patient population (Davis et al., 2012; 
Harris et al., 2012; Hess et al., 2006; Moore, Johnson, Cheng, Masuno, & 
Banerjee, 2005). 
Given the different sizes and compositions of each HBOC, it is currently 
unknown as to the full extent of these differences in terms of physiological effects 
and pharmacokinetics. In 2000, Sakai et al demonstrated that HBOC particle size 
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affected arterial constriction and hypertension, while a study by Tsai et al (2006) 
showed inconsistency in hypertensive effects based on HBOC molecular 
configuration (Sakai et al., 2000; Tsai et al., 2006). Therefore, it is not 
unreasonable to conclude that size affects the distribution of HBOCs, possibly 
affecting their mechanism of action. 
The specific HBOC of interest in this study is a bovine hemoglobin 
glutamer-250 known as HBOC-201. It is manufactured by the Biopure 
Corporation, now known as OPK Biotech, and consists of particles that weigh, on 
average, 250 kDA, or approximately four times the molecular weight of a 
standard endogenous hemoglobin tetramer. Its oxygen affinity (P50) is 
approximately 36 mmHg, while that of endogenous RBC hemoglobin is 13 
mmHg(Dube, Vranckx, & Greenburg, 2008; Standl et al., 2003). Oxygen affinity 
has a negative correlation with percent saturation. Therefore, this cross-linked 
bovine hemoglobin has a much lower affinity for oxygen than its endogenous 
counterpart. 
It is our hypothesis that administration of a HBOC will directly affect blood 
pressure, vascular resistance, and other cardiovascular parameters. Specifically, 
we predict there will be an increase in mean arterial pressure (MAP), systemic 
vascular resistance (decreased arteriolar diameter), and possibly heart rate. We 
also hypothesize that oxygen saturation will decrease, as evidenced by past 
studies on pulse oximetry and HBOC administration (Hughes et al., 1996). These 
parameters will display responses directly proportional to the dose of HBOC 
administered, producing a standard dose-response curve. 
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Methods 
Subjects and Instrumentation 
 A murine model was employed for this investigation, with male rats (spp. 
Rattus norvegicus; Sprague-Dawley) weighing 200-500 g being sedated via initial 
intraperitoneal (IP) injection of ketamine (75 mg/kg) and acepromazine (2.5 
mg/kg). After successful sedation, the femoral triangles, abdomen, and ventral 
neck were shaved and cleaned with ethyl alcohol. The subjects were placed on a 
normothermic (37˚C), heated conduction pad for facilitation of electrocautery. A 
patent airway was established via surgical tracheotomy and maintained for the 
duration of the experiment. 
After assurance of adequate ventilation, the right or left femoral vein was 
surgically isolated and cannulated for access to the central venous circulation 
and administration of additional intravenous (IV) anesthesia. Alfaxan (alfaxalone 
acetate; Jurox, Inc., Kansas City, MO) was administered at a rate of 0.1 
mg/kg/min to maintain general anaesthesia. A toe pinch was performed at 15-
minute intervals to assess for the effectiveness of anesthesia, and levels were 
adjusted appropriately. The right or left femoral artery was then surgically 
isolated and cannulated for hemodynamic monitoring, including mean arterial 
pressure (MAP), pulse pressure, and heart rate (HR). A second central venous 
line was inserted into the right or left internal jugular vein as a route for 
administration of test solutions. 
Surgical exteriorization and preparation of a unilateral section of 
spinotrapezius muscle was performed in order to isolate a segment of skeletal 
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muscle vasculature. (Gray, 1973) The isolated muscle was reflected and 
displayed over a heated (37˚C) Lexan polycarbonate (SABIC, Riyadh, Saudi 
Arabia) platform for viewing by intravital microscopy. The muscle was kept moist 
by the addition of normal saline and a Krehalon covering, which was also used to 
prevent atmospheric interference. At the conclusion of each experiment, the rats 
were euthanized by IV administration of 0.4 mL/kg Euthasol (pentobarbital 390 
mg/mL, phenytoin 50 mg/mL; Delmarva Laboratories, Midlothian, VA). All 
procedures and treatments were approved as part of this protocol by the VCU 
Institutional Animal Care and Use Committee. 
 
Physiological Monitoring 
Arterial blood pressure and heart rate were continuously measured after 
initial surgical instrumentation by a pressure transducer attached to the IV 
cannula in the carotid artery. Data for hemodynamic status were recorded using 
integrated software (BIOPAC Systems, Inc., Goleta, CA). Body temperature was 
continuously monitored by use of a rectal thermometer, and non-invasive pulse 
oximetry (Nonin PulseSense™, Nonin Medical, Inc., Plymouth, MN) provided 
data on SpO2 and HR. 
 
Treatment 
 Rats were divided into two study groups: HBOC-201 (Hemopure® bovine 
hemoglobin glutamer-250, Biopure® Corporation, Cambridge, MA) IV 
administration and Human Serum Albumin (Albumin, Human 25%, ZLB Behring 
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AG, Berne Switzerland) volume control IV administration. A top-load infusion was 
utilized for this study. As described in previous studies, a dose-response effect 
was sought by sequential administration of escalating doses of HBOC-201 and 
HSA control. The stock solution of 25% HSA was diluted to an iso-oncotic 
concentration of 5.9% (Mongan et al., 2009). Doses for HBOC-201 IV 
administration included Dose 1, 2 mg/kg; Dose 2, 22 mg/kg; Dose 3, 230 mg/kg; 
and Dose 4, 780 mg/kg. HSA control doses were administered to correspond 
with infused volumes of HBOC-201, and included Dose 1, 0.4 mL/kg; Dose 2, 0.4 
mL/kg; Dose 3, 3.8 mL/kg; and Dose 4, 13.1 mL/kg. Due to the inherent and 
relatively low blood volume of rats, the volumes of administered doses had to be 
adjusted accordingly by concentration to maintain a reasonable infusion volume. 
Therefore, the highest dose (13.1 mL/kg) was reduced to 6.55 mL/kg, and an 
undiluted stock solution of HBOC 201 was used. The subsequent control was 
also lowered to 6.55 mL/kg. 
 Rats were allowed an equilibration period of approximately 15 minutes 
prior to obtaining the baseline measurements and administering the first infusion. 
Each dose was administered at a rate of 1 mL/min, and a 10-minute interval 
between doses was observed. 
 
Microscopy 
 In vivo microcirculatory studies were performed by intravital microscopy 
(Figure 1) of the skeletal muscle vasculature using an Axioimager A1m 
microscope (Carl Zeiss Microscopy, LLC, Oberkochen, Germany). Each rat was  
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Figure 1. Intravital microscope diagram. Note: PMT was not used in this series of 
experiments, but remained as a part of the microscope setup. (Credit: 
Aleksander Golub) 
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Figure 2. Thermostatic platform. Shown with temperature regulator and pedestal 
for muscle preparation. (Credit for muscle prep picture: Aleksander Golub) 
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placed on its side on a thermostatic platform with a unilateral section of 
exteriorised and isolated spinotrapezius muscle reflected onto a pedestal (Figure 
2) (Golub & Pittman, 2003). The muscle preparation was stretched and secured 
via silk surgical suture and covered with a polyvinylidene chloride film (Krehalon, 
Kureha America, Inc., New York, NY). The film was secured to the pedestal via a 
neoprene ring and pushpins. 
 A Krehalon “bag” and modified hypodermic needle were secured to the 
objective lens via wrapping with electrical tape. The needle served to provide an 
inlet by which an air compressor could keep the air between the bag and 
objective lens at a constant pressure (8-12 mmHg), and electrical tape prevented 
any unwanted air escape. A small amount of transparent lubricant was applied to 
the Krehalon cover of the muscle preparation to reduce friction between it and 
the objective lens “bag”. 
 Randomly selected, isolated skeletal muscle arterioles with a diameter 
range of 30-80 µm were identified as sites for measurement during treatment, 
with three such sites identified for each rat. Baseline measurements were 
obtained after a short equilibration period, and included arteriolar diameter, MAP, 
pulse pressure, HR, and pulse oximetry (SpO2). After administration of the 
treatment or control solutions, measurements were reobtained. 
 
Statistical Analysis 
 Unless otherwise noted, all data are presented as mean ± standard error 
of the mean (SEM). An analysis of variance and F test were performed to detect 
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differences within groups and across doses, while a Tukey HSD test was utilised 
to determine significant differences among specific points. 
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Results 
Systemic Parameters 
Mean Arterial Pressure 
Figures 3 and 4 display the relationship between dose and MAP for the two 
treatment groups (HBOC-201 and 5.9% HSA). Tables 1 and 2 display a 
summary of the data and statistical analysis for all parameters. Overall (Figure 
5), there was a significant increase in MAP (p < 0.05) from baseline (102.70 ± 
2.32 mmHg, N = 13) to the two highest doses (3.8 mL/kg: 124.07 ± 3.18 mmHg, 
N = 13; 6.55 mL/kg: 121.69 ± 2.59 mmHg, N = 13), but there was no difference 
between the two lowest doses or between the two highest doses (Table 2). For 
specific comparisons, the 3.8 mL/kg (HBOC-201: 130.84 ± 3.77 mmHg, N = 7; 
5.9% HSA: 116.17 ± 3.07 mmHg, N = 6) and 6.55 mL/kg (HBOC-201: 125.87 ± 
2.70 mmHg, N = 7; 5.9% HSA: 116.82 ± 3.97 mmHg, N = 6) doses of both 
treatment solutions were significantly different (p < 0.05) from the other groups, 
though not from each other. 
 
Pulse Pressure 
 The relationship between pulse pressure and dose is displayed in Figure 
6. Summary statistics for pulse pressure can be found in Tables 1 and 2. No 
significant differences were found overall from baseline (48.16 ± 2.76 mmHg, N = 
13) or between the two treatment groups and across doses. Likewise, when 
considering the effects of treatment and dose together, no significant differences 
were found. 
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Figure 3. Dose-Response Bar Graph (MAP). HBOC-201 (N = 7) doses converted 
to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 6). 
Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2, 
22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg (~300 
µM). * denotes statistically significant difference (p < 0.05) from baseline. 
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Figure 4. Dose-Response Line Graph (MAP). HBOC-201 (N = 7) doses 
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); 
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg 
(~300 µM). * denotes statistically significant difference (p < 0.05) from baseline. 
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Figure 5. Combined Treatment Dose-Response (MAP). This figure represents 
the total mean (HBOC-201 and 5.9% HSA) change from baseline across doses. 
HBOC-201 (N = 7) doses converted to mL/kg to correspond to 5.9% HSA iso-
oncotic volume control (N = 6). Concentrations of HBOC-201 were as follows: 
Dose 1, 2 mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 
µM); Dose 4, 780 mg/kg (~300 µM). * denotes statistically significant difference 
(p < 0.05) from baseline. 
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Table 1. Summary statistics for systemic parameters by treatment group. HBOC-201 (N = 7) doses converted to mL/kg 
to correspond to 5.9% HSA iso-oncotic volume control (N = 6). Concentrations of HBOC-201 were as follows: Dose 1, 2 
mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg (~300 µM). SpO2 = 
oxygen saturation 
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Table 2. Summary statistics for systemic parameters not differentiated by treatment group. HBOC-201 (N = 
7) doses converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 6). Concentrations 
of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg 
(~100 µM); Dose 4, 780 mg/kg (~300 µM). SpO2 = oxygen saturation 
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Figure 6. Dose-Response Graph (Pulse Pressure). HBOC-201 (N = 7) doses 
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); 
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg 
(~300 µM). No statistically significant changes were noted in any comparisons, 
however, a slight upward trend can be seen in the graph. 
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Heart Rate 
 The relationship between heart rate and dose is displayed in Figure 7. 
Data pertaining to heart rate can be found in Tables 1 and 2. No significant 
differences from the baseline (312.69 ± 13.31, N = 13) were found between the 
two treatment groups, or across doses. Likewise, when considering the effects of 
treatment and dose together, no significant differences were found. 
 
Pulse Oximetry 
 The dose-response relationship between the pulse oximetry 
measurements and treatment is displayed in Figure 8. Tables 1 and 2 display the 
summary statistics for oxygen saturation (pulse oximetry). Overall, only one 
significant difference was noted among the doses, with the highest dose (6.55 
mL/kg: 86.31 ± 1.30, N = 13, p < 0.05) resulting in a lower pulse oximetry reading 
than the other doses. Across treatment groups and doses, the 6.55 mL/kg 
HBOC-201 dose (83.00 ± 1.35, N = 7, p < 0.05) produced significantly lower 
pulse oximetry readings than all other doses, with the exceptions of the 3.8 
mL/kg control (89.33 ± 1.28, N = 6, p = 0.1027) and HBOC-201 (87.57 ± 1.81, N 
= 7, p = 0.4322) doses. No other significant differences were observed. 
!!22!
Figure 7. Dose-Response Graph (Heart Rate). HBOC-201 (N = 7) doses 
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); 
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg 
(~300 µM). No statistically significant changes were noted in any comparisons, 
however, as with pulse pressure (Figure 6), a slight upward trend can be seen in 
the graph. 
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Figure 8. Dose-Response Graph (Oxygen Saturation). HBOC-201 (N = 7) doses 
converted to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 
6). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); 
Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg 
(~300 µM). * denotes statistically significant difference (p < 0.05) from baseline. Δ 
denotes statistically significant difference (p < 0.05) from control at the current 
dose. 
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Microvascular Parameters 
Arteriolar Diameter 
 Due to the wide range of vessel sizes (30-80 µm), data for arteriolar 
diameter changes are reported using percent (%) change from baseline (Figure 
9). A positive change indicates an increase in arteriolar diameter, whereas a 
negative change indicates a decrease. Arterioles were divided into three groups, 
those most distal (HBOC-201: 4.40 ± 1.29, N = 12; 5.9% HSA: 1.89 ± 2.00, N = 
16), proximal (HBOC-201: 4.77 ± 2.81, N = 12; 5.9% HSA: 5.86 ± 2.44, N = 16), 
and a distance between the two extremes (HBOC-201: 7.35 ± 2.51, N = 12; 5.9% 
HSA: -2.04 ± 1.75, N = 13), with each vessel being compared to others in its 
group. Diameter changes were also compared across location groups and doses, 
as well as overall treatment by itself (HBOC-201 v. 5.9% HSA). No significant 
differences in arteriolar diameter were noted across any groups. 
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Figure 9. Dose Response Graph (Vascular Resistance). Results expressed as % 
change due to wide variation in vessel sizes. HBOC-201 (N = 9) doses converted 
to mL/kg to correspond to 5.9% HSA iso-oncotic volume control (N = 11). 
Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2, 
22 mg/kg (~10 µM); Dose 3, 230 mg/kg (~100 µM); Dose 4, 780 mg/kg (~300 
µM). Three vessel sites were chosen in each muscle preparation, with N = 4 
(5.9% HSA) and N = 3 (HBOC-201). No statistically significant differences were 
noted from baseline, or between treatment groups. 
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Discussion 
The results of this study suggest a plateau in the effect of HBOC-201 in 
regard to dose-response. As the dose of HBOC-201 increased, the MAP also 
increased, but only to a certain point. This serves to demonstrate a sigmoid curve 
rather than a direct linear relationship between dose and cardiovascular 
response. While very little statistical significance was found, there is an obvious 
trend in the data for MAP that suggests a closer association between dose and 
pressure. Results for the second lowest dose of HBOC-201, while not statistically 
significant, appears to produce a higher MAP than the HSA control. This is 
consistent with recent, similar studies that suggest no significant difference in 
MAP between the control and HBOC treatments (Song et al., 2013; Song, 
Nugent, Moon-Massat, & Pittman, 2014). 
No statistically significant differences were found with either the pulse 
pressure or heart rate parameters; however, slight trends were noticed in the 
graphed data. A slight and gradual increase in both parameters can be seen, 
though both the HSA control and HBOC-201 groups tended to mimic each other 
in magnitude of response. One point of interest is the fact that the average heart 
rate appeared consistently higher in the HSA control group than in the HBOC-
201 group, though not significantly so. 
Pulse oximetry was the only other parameter to show a significant change. 
The HSA control appeared to stay fairly consistent throughout the experiment 
with regard to SpO2, while the HBOC-201 treatment group showed a dramatic 
and obvious decrease after the two highest doses. These data are consistent 
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with previous studies showing a decrease in oxygen saturation after 
administration of a cell-free HBOC solution(Hughes et al., 1996). The artificially 
decreased affinity for oxygen of HBOC-201 appears to be the cause of lower 
pulse oximetry readings, however, previous studies have shown a much lower 
magnitude of change compared to the results described here. The use of a 
murine model may have contributed to the increased magnitude of change seen 
in this study, but further research will have to be performed in order to determine 
this effect. 
Interestingly, as stated before, there was an observed lack of arteriolar 
response to HBOC-201 administration. Coupled with the lack of change in heart 
rate, it is curious to note the much more obvious increase in MAP. Control of 
MAP can be reduced to three main components: cardiac output, systemic 
vascular resistance (SVR), and blood volume. This model attempts to control for, 
and measure, each component of this system in some way. Cardiac output can 
be determined by multiplying heart rate and stroke volume, of which we directly 
measured heart rate in two ways (non-invasive pulse oximetry and arterial 
catheter placement). Systemic vascular resistance was directly measured by 
intravital microscopy of skeletal muscle arterioles, which leads to indirect 
calculation of regional blood flow, even though flow was not directly measured. 
Finally, blood volume changes were accounted for by administration of a control 
solution of iso-oncotic 5.9% human serum albumin to prevent fluid shift into or 
out of the interstitial space after administration. The 5.9% HSA was also used as 
the diluent for varying the HBOC-201 concentrations. 
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Based on the results of this study, and the lack of change in several 
parameters that directly affected blood pressure, we are led to infer that an 
increase in stroke volume may have occurred that resulted in an overall increase 
in MAP. Cardiac output was not directly measured in this set of experiments, 
though the placement of a flow probe or thermodilution catheter may provide 
better insight into the cause of the blood pressure increase(Phillips et al., 2012; 
Swan et al., 1970). 
As originally stated, several doses of HBOC-201 were used, representing 
2, 22, 230, and 780 mg/kg. While the doses were converted to a consistent 
volume relative to the HSA control solution, one variable remained unaccounted 
for. One central venous catheter was used for administration of each dose, with 
each syringe being replaced by the next with a higher dose. Unfortunately, the 
dead space in the catheter and hub was not insignificant, accounting for 
approximately 0.6 mL of volume. The average volume of the first infusion was 
0.14 mL, and the average total volume infused was 3.95 mL. Inadvertent and 
unavoidable inter-infusion doses of 0.6 mL occurred with each syringe change, 
adding a total of 1.2 mL to the total dose. These inter-infusion doses were 
consistent across all subjects, occurring with approximately the same volume 
and time between each syringe change. Unfortunately, it is currently unknown if 
or how these extra boluses affected the above-described parameters. 
In brief, the results of this study demonstrate that HBOC-201 does not 
have any more effect on several cardiovascular parameters than an iso-oncotic 
volume control. This is in direct contrast with previous studies using many 
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different models, (Caron, Malfatti, Aguejouf, Faivre-Fiorina, & Menu, 2001; 
Freilich et al., 2009; Vogel, Dennis, Cassidy, Apstein, & Valeri, 1986; Winslow et 
al., 1998; Winslow, 2004) though compared to systemic studies, few 
microvascular studies have been performed to shed light on this issue. These 
results do correspond, however, to similar, recently published studies on rat 
mesentery and skeletal muscle microvascular effects(Song et al., 2013; Song et 
al., 2014). The lack of difference between the HBOC-201 and iso-oncotic volume 
control seems to point to volume expansion as the main culprit behind the 
hypertensive effect, and not a property of HBOC-201, itself. As the NO 
scavenging hypothesis relies on this specific property of HBOC-201, it is clear 
that this effect is minimal at best, if present at all. Several past studies utilized 
other volume controls, such as isotonic or hypertonic crystalloids and colloids, 
similar to those used in clinical practice. This, however, allows for much broader 
variation in fluid dynamics in the body, as these fluids may rapidly leave the 
vascular space, which an endogenous iso-oncotic fluid would likely avoid 
(Mazzoni, Borgstrom, Arfors, & Intaglietta, 1988; Quinlan, Martin, & Evans, 
2005). 
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Table 3. Summary statistics for vascular resistance. HBOC-201 (N = 9) doses converted to mL/kg to correspond to 5.9% HSA iso-oncotic 
volume control (N = 11). Concentrations of HBOC-201 were as follows: Dose 1, 2 mg/kg (~1 µM); Dose 2, 22 mg/kg (~10 µM); Dose 3, 230 
mg/kg (~100 µM); Dose 4, 780 mg/kg (~300 µM). Three vessel sites were chosen in each muscle preparation, with N = 4 (5.9% HSA) and N 
= 3 (HBOC-201). No statistically significant differences were noted from baseline, or between treatment groups. 
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